High Court Review Of 3rd Circuit's Antitrust Standing Rule Is Denied

High Court Review Of 3rd Circuit's Antitrust Standing Rule Is Denied

WASHINGTON, D.C. - The U.S. Supreme Court on Oct. 1 denied a pharmaceutical drug developer's petition seeking review of a Third Circuit U.S. Court of Appeals ruling that the developer did not have antitrust standing to sue pharmaceutical marketers for entering into an anti-competitive agreement (SigmaPharm, Inc. v. Mutual Pharmaceutical Company, Inc., et al., No. 11-1275, U.S. Sup.).

Find full version on lexis Advance®
Access this news story on lexis.com®